




+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	10/691,928
Filing Date	October 23, 2003
First Named Inventor	Jay A. Goldstein
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	JAG 100

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/NWS/		4,912,124		Das, et al.	03-27-1990	
		5,002,938		Wang, et al.	03-26-1991	
		5,021,458		Maeda, et al.	06-04-1991	
		5,110,809		Wang, et al.	05-05-1992	
		5,174,475		Day, et al.	12-29-1992	
		5,219,877		Shah, et al.	06-15-1993	
		5,310,545		Eisen	05-10-1994	
		5,407,663		Eisen	04-18-1995	
		6,075,056		Quigley, Jr., et al.	06-13-2000	
/NWS/		6,080,744		Ayon-Covarrubias	06-27-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)				

Examine Signature	/Nathan Schlientz/	Date Considered	08/02/2007
-------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	10/691,928
Filing Date	October 23, 2003
First Named Inventor	Jay A. Goldstein
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	JAG 100

Sheet	2	of	2
-------	---	----	---

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/NWS/		ADAMS, et al., "Perianal ulcerations from topical steroid use," <i>Cutis</i> 69(1): 67-68 (2002).	
		BARSKY, "Clinical comparison of desonide cream with fluocinonide cream in steroid-responsive dermatologic disorders," <i>Cutis</i> 18(6): 826-30 (1976).	
		FLEMING, et al., "An inflammatory eruption associated with recombinant human IL-6," <i>Brit. J. Dermatol.</i> 130(4): 534-40 (1994).	
		GREENBERG, et al., "Clotrimazole/betamethasone dipropionate: a review of costs and complications in the treatment of common cutaneous fungal infections," <i>Pediatr. Dermatol.</i> 19(1): 78-81 (2002).	
		JORIZZO, et al., "Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients," <i>J. Am. Acad. Dermatol.</i> 33(1): 74-7 (1995).	
		LUCKY, et al., "Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis," <i>Cutis</i> 59(3): 151-153 (1997).	
/NWS/		WEINSTEIN & BERMAN, "Topical treatment of common superficial tinea infections," <i>Am. Fam. Physician</i> 65(10): 2095-2102 (2002).	


Examiner's Signature	/Nathan Schlientz/	Date Considered	08/02/2007
----------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO



(use as many sheets as necessary)

10/691.928

October 23, 2003

Jay Goldstein

1616

JAG 100

1

of

1

[illegible][illegible]

08/02/2007

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/691,928
		Filing Date	October 23, 2003
		First Named Inventor	Jay A. Goldstein
		Group Art Unit	1616
		Examiner Name	Nathan W. Schlientz
Sheet	1	of	1
		Attorney Docket Number	JAG 100

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ¹
/NWS/		FLEISCHER, et al., "Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians", <i>Clin. Ther.</i> , 21:1725-31 (1999)	
↓		HENGGE, et al., <i>J. Am. Acad. Dermatol.</i> , "Adverse effects of topical glucocorticosteroids", 54:1-15 (2006)	
↓		SHAFFER, et al., "Use of clotrimazole/betamethasone dipropionate by family physicians", <i>Fam. Med.</i> , 32:561-5 (2000)	
↓		SMITH, et al., "Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994", <i>J. Am. Acad. Dermatol.</i> , 39:43-47 (1998)	
/NWS/		STERN, <i>J. Am. Acad. Dermatol.</i> , "The pattern of topical corticosteroid prescribing in the United States, 1989-1991", 35:183-6 (1996)	

Examiner's Signature	/Nathan Schlientz/	Date Considered	08/02/2007
----------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <h1 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete If Known <table border="1"> <tr> <td>Application Number</td> <td>10/691,928</td> </tr> <tr> <td>Filing Date</td> <td>October 23, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Jay A. Goldstein</td> </tr> <tr> <td>Group Art Unit</td> <td>1616</td> </tr> <tr> <td>Examiner Name</td> <td>Nathan W. Schlientz</td> </tr> <tr> <td>Attorney Docket Number</td> <td>JAG 100</td> </tr> </table>		Application Number	10/691,928	Filing Date	October 23, 2003	First Named Inventor	Jay A. Goldstein	Group Art Unit	1616	Examiner Name	Nathan W. Schlientz	Attorney Docket Number	JAG 100
Application Number	10/691,928																
Filing Date	October 23, 2003																
First Named Inventor	Jay A. Goldstein																
Group Art Unit	1616																
Examiner Name	Nathan W. Schlientz																
Attorney Docket Number	JAG 100																
Sheet	1	of	1														

[illegible][illegible]

Examiner's Signature	<i>Nash L. Holt</i>	Date Considered	8/2/07
-------------------------	---------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.